Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma

Key Inclusion Criteria: * Eastern Cooperative Oncology Group Performance Status of 0 or 1. * Histologically confirmed esophageal squamous cell carcinoma (ESCC). * Stage cT1-2N+M0 and cT3NanyM0 (per The American Joint Committee on Cancer 8th Edition). * Evaluation by the investigator to confirm eligibility for an R0 resection with curative intent. * Adequate hematologic and organ function, defined by protocol-specified laboratory test results obtained within 14 days before first dose. Key Exclusion Criteria: * Ineligible for treatment with any of the chemotherapy doublets of protocol-specified chemotherapy. * Any prior therapy for current ESCC, including investigational agents, chemotherapy, radiotherapy, targeted therapy agents, or prior therapy with an anti-programmed cell death protein-1, anti-programmed cell death protein ligand-1, anti-programmed cell death protein ligand-2, or any other antibody or drug specifically targeting T-Cell co-stimulation or checkpoint pathways. * History of fistula due to primary tumor invasion. * Participants with high risk of fistula or sign of perforation evaluated by investigator. * Any condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days before first dose. \* Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent) and topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal sys…